192 related articles for article (PubMed ID: 210235)
41. Inotropic responses to selective (RO 20-1724 and SQ 65,442) and nonselective (trequinsin) inhibitors of cyclic AMP-specific class IV phosphodiesterase in newborn, immature, and adult rabbit myocardium.
Oquist NL; Strada SJ; Artman M
Pediatr Res; 1992 Mar; 31(3):300-4. PubMed ID: 1313959
[TBL] [Abstract][Full Text] [Related]
42. Activities of 3':5' cyclic nucleotide phosphodiesterases in the superior cervical ganglion of rat: characterization, compartmentalization and observations in young and old animals.
Giorgi M; Squitti R; Bonsi P; Paggi P; Toschi G
Neurochem Int; 1994 Nov; 25(5):493-500. PubMed ID: 7849578
[TBL] [Abstract][Full Text] [Related]
43. On the mechanism of relaxation of tracheal muscle by theophylline and other cyclic nucleotide phosphodiesterase inhibitors.
Fredholm BB; Brodin K; Strandberg K
Acta Pharmacol Toxicol (Copenh); 1979 Nov; 45(5):336-44. PubMed ID: 231892
[TBL] [Abstract][Full Text] [Related]
44. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
[TBL] [Abstract][Full Text] [Related]
45. Role of cyclic AMP in differentiation of human neuroblastoma cells in culture.
Prasad KN; Kumar S
Cancer; 1975 Oct; 36(4):1338-43. PubMed ID: 240503
[TBL] [Abstract][Full Text] [Related]
46. 1-(4-Aminobenzyl)-and 1-(4-aminophenyl)isoquinoline derivatives: synthesis and evaluation as potential irreversible cyclic nucleotide phosphodiesterase inhibitors.
Walker KA; Boots MR; Stubbins JF; Rogers ME; Davis CW
J Med Chem; 1983 Feb; 26(2):174-81. PubMed ID: 6298424
[TBL] [Abstract][Full Text] [Related]
47. Selective inhibition of two soluble adenosine cyclic 3',5'-phosphate phosphodiesterases partially purified from calf liver.
Yamamoto T; Lieberman F; Osborne JC; Manganiello VC; Vaughan M; Hidaka H
Biochemistry; 1984 Feb; 23(4):670-5. PubMed ID: 6324851
[TBL] [Abstract][Full Text] [Related]
48. Dihydro- and tetrahydroisoquinolines as inhibitors of cyclic nucleotide phosphodiesterases from dog heart. Structure-activity relationships.
Van Inwegen RG; Salaman P; St Georgiev V; Weinryb I
Biochem Pharmacol; 1979 Apr; 28(8):1307-12. PubMed ID: 87199
[No Abstract] [Full Text] [Related]
49. Effects of phosphodiesterase inhibitors, imidazole and phosphate on cyclic CMP phosphodiesterase are different from those on cyclic AMP and cyclic GMP phosphodiesterases.
Kuo JF; Shoji M; Brackett NL; Helfman DM
J Cyclic Nucleotide Res; 1978 Dec; 4(6):463-74. PubMed ID: 85641
[TBL] [Abstract][Full Text] [Related]
50. Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
Davey DD; Erhardt PW; Cantor EH; Greenberg SS; Ingebretsen WR; Wiggins J
J Med Chem; 1991 Sep; 34(9):2671-7. PubMed ID: 1654425
[TBL] [Abstract][Full Text] [Related]
51. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form.
Lavan BE; Lakey T; Houslay MD
Biochem Pharmacol; 1989 Nov; 38(22):4123-36. PubMed ID: 2480793
[TBL] [Abstract][Full Text] [Related]
52. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R
Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457
[TBL] [Abstract][Full Text] [Related]
53. The metabolism of cyclic nucleotides in the guinea-pig pancreas. Cyclic AMP phosphodiesterase and cyclic GMP phosphodiesterase.
Methven P; Lemon M; Bhoola K
Biochem J; 1980 Feb; 186(2):491-8. PubMed ID: 6246887
[TBL] [Abstract][Full Text] [Related]
54. The effects of theophylline and 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO 20-1724) on protein secretion from rat parotid gland.
Afari G; Tenenhouse A; Vachon C
Br J Pharmacol; 1982 Nov; 77(3):405-11. PubMed ID: 6291691
[TBL] [Abstract][Full Text] [Related]
55. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells.
Shimizu E; Kobayashi Y; Oki Y; Kawasaki T; Yoshimi T; Nakamura H
Life Sci; 1999; 64(23):2081-8. PubMed ID: 10372650
[TBL] [Abstract][Full Text] [Related]
56. 1-(4-Aminophenyl)isoquinoline derivatives. Potent inhibitors of calcium-independent and calcium-dependent phosphodiesterases from rat cerebral cortex.
Davis CW; Walker KA
Biochem Pharmacol; 1984 Apr; 33(8):1205-12. PubMed ID: 6324818
[TBL] [Abstract][Full Text] [Related]
57. Cyclic nucleotide-phosphodiesterase in the uninvolved and involved skin of psoriasis.
Iizuka H; Adachi K; Halprin KM; Levine V
J Invest Dermatol; 1978 May; 70(5):246-9. PubMed ID: 205615
[TBL] [Abstract][Full Text] [Related]
58. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
59. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
Bellamy TC; Garthwaite J
Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
[TBL] [Abstract][Full Text] [Related]
60. Cyclic GMP metabolism in psoriasis: increased activity of soluble epidermal cyclic GMP phosphodiesterase and its modulation by calcium.
Cantieri JS; Graff G; Goldberg ND
Br J Dermatol; 1981 Mar; 104(3):301-5. PubMed ID: 6260127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
